Star Combo Announces FY2018 Results

09
Sep

Highlights

• Record full year revenue of $10.9million, up 10.8% on prior year.

• Underlying Profit is in line with expectations

• IPO costs(one-off) and non-cash share based payments expenses impact FY2018 profit

The Company has pleasure in announcing its operating results for the year ended 30 June 2018.

Revenue growth

Star Combo Pharma Ltd (“The Company or Star Combo”) derives its revenue through the manufacture and sale of vitamins and dietary supplements.